Stockreport

Alnylam Pharmaceuticals: Cutting-Edge Pharma Stock Still Feels A Little Overvalued [Seeking Alpha]

Alnylam Pharmaceuticals, Inc.  (ALNY) 
Last alnylam pharmaceuticals, inc. earnings: 2/6 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.alnylam.com/investor-overview
PDF 2026 guidance targets $5.1bn–$5.5bn revenue, ~38% growth, and operating profit potentially near $1.8bn, positioning ALNY closer to Big Pharma metrics. Pipeline progre [Read more]